Portfolio
Today a project: tomorrow a treatment
Partnering with IRICoR means leveraging OUR expertise, resources and network to accelerate YOUR drug discovery projects, reduce risks and improve the chances of a successful market launch.
Partnered
| indication | discovery | hit id | h2l | lead opt | ind enabling | clinical phase | partner |
|---|---|---|---|---|---|---|---|
|
Zemcelpro® (dorocubicel) ex vivo cell expansion Cell transplant, Small molecule (UM-171) |
Phase 2 – EC authorization (EMA) |
|
|||||
|
PAR4 Thrombosis, Small molecule (UDM-003183, now BMS-986141) |
Phase 2 |
 |
|||||
|
PAR4 Thrombosis, Small molecule (UDM-002985, now BMS-986120) |
Phase 1 |
|
|||||
|
RAF Inhibitor Solid Tumors, Small molecule |
Phase 1 |
 |
|||||
|
Tumor Specific Antigens Liquid and Solid Tumors, Therapeutic Cancer Vaccines |
 |
||||||
|
Undisclosed GPCR CV/HF, Small molecule |
 |
||||||
|
Melanocortin-4 receptor (MC4R) pharmacochaperone Metabolic disorder, Small molecule |
 |
||||||
|
Undisclosed #2 Solid tumors, Small molecule |
|
||||||
|
Undisclosed GPCR IPF, Small molecule |
|
||||||
|
ETC1 Leukemia and solid tumors, Small molecule |
 |
||||||
|
CoREST1 degrader Oncology, Small molecule |
|
||||||
|
CyclinK degrader Oncology, Small molecule |
|
||||||
|
Undisclosed degrader Aging (epigenetics), Small molecule |
|
Partnering opportunities
| Indication | Discovery | Hit ID | H2L | Lead Opt | IND Enabling | Clinical phase | Academic Partner |
|---|---|---|---|---|---|---|---|
|
YES/SRC Dual kinase inhibitor Solid tumors, Small molecule |
 |
||||||
|
elF4A inhibitor Breast cancer and Solid tumors, Small molecule |
 |
||||||
|
Proteasome inhibitors Pediatric AML, Small molecule |
|
||||||
|
SLAM7 Multiple Myeloma, mAb |
 |
||||||
|
mKEAP1/NRF2 inhibitor Chemoresistance, Small molecule |
 |
||||||
|
Neuraminidase Idiopathic Thrombocytopenic Purpura (ITP), Small molecule |
 |
||||||
|
ATG5 Metabolic Fitness Cell therapy, CAR-T |
 |
||||||
|
Undisclosed TSA AML, Monoclonal antibody |
|
||||||
|
ERK3/4 Solid tumors, Small molecule |
|
||||||
|
Undisclosed Solid tumors, Antibody drug conjugate |
|
||||||
|
Undisclosed MAPK related target #1 Solid tumors, Small molecule |
|
||||||
|
Undisclosed MAPK related target #2 Solid tumors, Small molecule |
|
Drug Discovery Platforms / Tools
| Projects | Discovery | Validation -POC | In operation – Active-Functional – InForce | Commercialization | Partner |
|---|---|---|---|---|---|
|
BRET Biosensors Drug Discovery Platform, BRET Biosensor |
|
||||
|
DNA Encoded Library (DEL) Drug Discovery Platform, DNA Encoded Library (DEL) |
|||||
|
Multiplexed Biosensors Drug Discovery Platform, Biosensor Multiplexing Technology |
|
